leadforensics

Our website uses cookies

Cookies are small text files held on your computer. They allow us to give you the best browsing experience possible and mean we can understand how you use our site. Some cookies have already been set. You can delete and block cookies but parts of our site won't work without them. By using our website you accept our use of cookies. Find out more about cookies.

Click here to dismiss this banner

PRESS RELEASE

...see all

Global Contraceptive Devices Market Set To Grow To $18.7bn By 2022

LONDON, UK. December 2017: Visiongain has launched a new pharma report Global Contraceptive Devices Market Forecast to 2027: Male Condoms, Female Condoms, Diaphragms, Sponges, Vaginal Rings, Subdermal/Contraceptive Implants, Intra-uterine Devices (IUDs), Copper IUD, Hormonal IUD.

The evolution of contraceptive devices has opened a new outlook in the healthcare industry. Growth rate exhibited by the contraceptive devices market despite the shortages and lack of awareness among the population in various countries, confirms the positive growth prospects going ahead. The contraceptive devices market is highly competitive and has reached maturity resulting in single digit growth rates of prominent devices such as condoms, diaphragms, vaginal rings, sponges, etc.

The lead analyst of the report commented The global contraceptive devices market is expected to experience a significant growth over the forecast period. The main drivers for the growth include rapid growth in population, development of technologically advanced contraceptive devices, huge burden of sexually transmitted diseases and HIV, increasing adoption of contraceptive devices and supportive government authorities.

The rising prevalence of sexually transmitted diseases (STDs) is increasing the need of more innovative products in the contraceptive devices market. At present, condoms are the only contraceptive devices that prevent from the risk of sexually transmitted infections & HIV therefore; manufacturers across the globe are enormously investing in R&D to come up with a product that would be reminiscent of contraceptive condoms in the prevention of sexually transmitted infections & HIV along with unintended pregnancies and birth control.”

Leading companies featured in the report include Bayer AG, Reckitt Benckiser Group plc, Merck Sharp & Dohme Corp., Church & Dwight Co., Inc., Teva Pharmaceutical Industries, Ltd., Allergan plc, Ansell Limited (Now Humanwell), The Female Health Company (a division of VERU Inc.), Karex Industries, Mayer Laboratories, Kessel Medintim GmbH, Okamato Industries, Inc., Agile Therapeutics, Inc., Eurogine S.L.

 

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.
 

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports cusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

read more

You have successfully subscribed. Thank you.

An internal error has occurred. Please try again later.

close